Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth (NASDAQ: CGC) became the first U.S.-traded marijuana company when it listed in 2018, following a reverse merger in Canada. The stock surged as investors anticipated growth from legalization in more regions, but the sector failed to meet expectations and investors grew disenchanted, pushing the stock into penny-stock territory.

In early 2026, Canopy Growth underwent a strategic recapitalization, reducing debt by issuing equity and acquiring MTL Cannabis, a Canadian medical marijuana company. This left the company with more shares, diluting current shareholders. In the first quarter of fiscal 2027, Canopy Growth reported a 13% year-over-year revenue growth, with all business divisions contributing to the improvement.

Its Canadian medical marijuana business grew by 22%, adult-use by 10%, international cannabis by 10%, and its Storz & Bickel business by 6%. Gross margin improved to 27%, and net loss decreased by 68% from the previous year. Despite the improvement, the stock remains a high-risk investment due to the dilution from share count increase and the company's history of falling short of investor expectations.

While the marijuana sector may be undergoing consolidation, the stocks most likely to benefit are not yet clear, making Canopy Growth a questionable choice for most investors at this time.